Oxidative stress and mitochondrial dysfunction in neurodegeneration

Current Opinion in Neurology

Volumn 9, Issue 4, 1996, Pages 260-264

  Schapira, A H V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; AMYLOID BETA PROTEIN; CYTOCHROME C OXIDASE; FREE RADICAL; SUCCINATE DEHYDROGENASE (UBIQUINONE);

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIUM; ENERGY METABOLISM; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; INBORN ERROR OF METABOLISM; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; REVIEW;

EID: 0029743756     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199608000-00003     Document Type: Review

References (49)

1. Kounnas MA, Moir RD, Rebeck GW, Buch AI, Argraves WS, Tanzi RE, Hyman BT: LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995, 82:331-340.
2. Pike CJ, Cummings BJ, Cotman CW: β-Amyloid induces neuritic dystrophy in vitro: similarities with Alzheimer pathology. NeuroReport 1992, 3:769-772.
3. Mattson MP, Cheng B, Davis D, Biyant K, Lieberburg I, Rydel RE: β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992, 12:376-389.
4. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA: A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci U S A 1994, 91:3270-3274.
5. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM: Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 1995, 131:193-202. β-Amyloid (1-40) induces free radical damage in hippocampal neurone cultures, an elegant demonstration of protein carbonyl content.
6. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M: β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168-171. The authors discuss the potential physiological role of β-amyloid in vascular control.
7. Kaneko I, Yamada N, Sukaraba Y, Kamenosono M, Tutumi S: Suppression of mitochondrial succinate dehydrogenase, a primary target of β-amyloid, and its derivative racemized at Ser residue. J Neurochem 1995, 65:2585-2593.
8. Askanas V, Serdaroglu P, Engle WK, Alvarez RB, Selkoe DJ: Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol 1994, 144:177-187.
9. Askanas V, McFerrin J, Baqué S, Alvarez RB, Sarkazi E, Engel WK: Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996, 93:1314-1319. Transfer of the β-APP gene into normal human muscle fibres induces reduced cytochrome oxidase activity - an interesting model for AD.
10. Oldfors A, Moslemi AR, Fyhr IM, Holme E, Larsson NG, Lindberg C: Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. J Neuropathol Exp Neurol 1995, 54:581-587.
11. Blass JP, Gibson GE: The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. J Neurochem 1993, 60:1964-1967.
12. Duara R, Grady C, Haxby J, Sudaram M, Cutler NR, Heston L, Moore A, Schlageter N, Larson S, Rapoport SI: Positron emission tomography in Alzheimer's disease. Neurology 1986, 36:879-887.
13. Haxby JV, Grady CL, Durra R, Schlageter NL, Berg G, Rapoport SI: Neocortical metabolic abnormalities precede nonmemory cognitive deficits in early Alzheimer-type dementia. Arch Neurol 1986, 43:882-885.
14. 31P NMR profiles in Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989, 39: 1423-1427.
15. Sims NR, Finegan JM, Blass JP, Bowen DM, Neary D: Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 1987, 436:30-38.
16. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer's cases, including 13 serial scans. Can J Neurol Sci 1990, 171:1-11.
17. Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, Golomb J, Ferris SG, Reisberg B, Ciaravino J: Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications. Arch Neurol 1992, 49:1142-1150.
18. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD: Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 1994, 5:36-41.
19. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:828-829.
20. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996, 334:752-758. An interesting demonstration of preclinical positron emission tomography abnormalities in patients homozygous for the apolipoprotein ε4 allele.
21. Parker WD, Parks J, Filley CM, Kleinschmidt-DeMasters BK: Electron transport chain defects in Alzheimer's disease. Neurology 1994, 44:1090-1096.
22. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang L-J, Wilson JM, DiStefano LM, Nobrega JN: Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992, 59:776-779.
23. Cooper JM, Wischik C, Schapira AHV: Mitochondrial function in Alzheimer's disease. Lancet 1993, 341:969-970.
24. Mutisya EM, Bowling AC, Beal MF: Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994, 3:2179-2184.
25. Chagnon P, Bétard C, Robitaille Y, Cholette A, Gauvreau D: Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Mol Neurosci 1995, 6:711-715.
26. Simonian N, Hyman BT: Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 1993, 52:580-585.
27. Simonian N, Hyman BT: Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol 1994, 53:508-512.
28. Chandrasekaran K, Giordano T, Brady DR, Stoll J, Martin LJ, Rapoport SI: Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer's disease. Mol Brain Res 1994, 24:336-340.
29. Shoffner JM, Brawn MD, Torrino A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R et al: Mitochondrial DNA variants observed in Alzheimer's disease and Parkinson's disease patients. Genomics 1993, 17:171-184.
30. Hutchin T, Cortopassi G: A mitochondrial DNA clone is associated with increased risk for Alzheimer's disease. Proc Natl Acad Sci U S A 1995, 92:6892-6895. An interesting but controversial result suggesting a particular polymorphism in an mtDNA tRNA gene is present at increased frequency in AD.
31. Mecocci P, MacGarvey U, Beal MF: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994, 36:747-751.
32. Benzi G, Moretti A: Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 1995, 16:661-674. An excellent and comprehensive review of free radicals in AD.
33. Lovell MA, Ehmann WD, Butler SM, Markesbery WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain of Alzheimer's disease. Neurology 1995, 45:1594-1601. Additional evidence to support the presence of oxidative stress in AD.
34. Balazs L, Leon M: Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 1994, 19:1131-1137.
35. Hensley K, Hall N, Sabramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA: Brain regional correspondence between Alzheimer's disease histopathology and biomarkers for protein oxidation. J Neurochem 1995, 65:2146-2156. The authors demonstrated an increased protein carbonyl content in AD hippocampus.
36. Hartley A, Cooper JM, Schapira AHV: Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res 1993, 627:349-353.
37. Thomas PK, Cooper JM, King RHM, Workman JM, Schapira AHV, Goss-Sampson MA, Muller DPR: Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. J Anat 1993, 183:451-461.
38. Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch EC, Mandell J-L: Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nature Genet 1995, 10:104-110. It was demonstrated that mutant and wild type huntingtin were widely coexpressed.
39. Gutekunst CA, Levey AI, Hehman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, Hersch SM: Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 1995, 92:8710-8714. Monoclonal and polyclonal antihuntingtin antibodies used for immunohistochemical studies on intracellular distribution demonstrating association with microtubules. The authors also showed that in lymphoblasts the higher the number of CAG repeats, the lower the amount of mutant protein.
40. 1H NMR spectroscopy. Neurology 1993, 43:2689-2695.
41. Koroshetz WJ, Jenkins B, Rosen B, Beal MF: Ubiquinone lowers occipital lactate levels in patients with Huntington's disease [Abstract]. Neurology 1993, 43:A334.
42. Brouillet E, Hantraye P, Ferrante RJ, Leroy-willig A, Kowall NW, Beal MF: Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995, 92:7105-7109. 3-Nitropropionic acid induces a close pathological model of Huntington's disease in non-human primates.
43. Gu M, Cooper JM, Gash M, Javoy-Agid F, Schapira AHV: Mitochondrial respiratory chain abnormal function in Huntington's disease chorea. Ann Neurol 1996, 39:385-389. A biochemical parallel in Huntington's disease to the finding of mitochondrial dysfunction in the 3-nitropropionic acid model.
44. Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, Vance JM, Strittmatter WJ: Huntingin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med 1996, 2:347-350. Glyceraldehyde-3-phosphate dehydrogenase binds huntingtin. The relationship of this to pathogenesis in Huntington's disease is unclear as this enzyme has a variety of functions.
45. Chen I, Bonilla E, Sciacco M, Schon EA: Paucity of deleted mitochondrial DNAs in brain regions of Huntington's disease patients. Biochem Biophys Acta 1995, 1271:229-233.
46. Horton TM, Graham BH, Corral-Debrinski M, Shoffner JM, Kaufman AE, Beal MF, Wallace DC: Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology 1995, 45:1879-1883.
47. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX: Motor neuron degeneration in mice that express a human CuZn superoxide dismutase mutation. Science 1994, 264:772-775.
48. Wiedau-Pazos M, Goto JJ, Rabizadeh S, Gralla EB, Ros JA, Lee MK, Valentine JS, Bredesen DE: Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996, 271:515-518. Amyotrophic lateral sclerosis CuZn superoxide dismutase mutations may enhance free radical production through peroxidation.
49. Przedborski S, Donaldson D, Jakowec M, Kish SJ, Guttman M, Rosoklija G, Hays AP: Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann Neurol 1996, 39:158-165. Evidence to support oxidative stress in amyotrophic lateral sclerosis.